Black Diamond Therapeutics (BDTX) Competitors $2.43 -0.12 (-4.71%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BDTX vs. CGEN, INBX, SPPI, ITOS, CCCC, CDXC, IGMS, ABVX, HUMA, and ATXSShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Compugen (CGEN), Inhibrx (INBX), Spectrum Pharmaceuticals (SPPI), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), ChromaDex (CDXC), IGM Biosciences (IGMS), ABIVAX Société Anonyme (ABVX), Humacyte (HUMA), and Astria Therapeutics (ATXS). These companies are all part of the "medical" sector. Black Diamond Therapeutics vs. Compugen Inhibrx Spectrum Pharmaceuticals iTeos Therapeutics C4 Therapeutics ChromaDex IGM Biosciences ABIVAX Société Anonyme Humacyte Astria Therapeutics Black Diamond Therapeutics (NASDAQ:BDTX) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Do analysts rate BDTX or CGEN? Black Diamond Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 537.86%. Compugen has a consensus price target of $4.00, suggesting a potential upside of 179.72%. Given Black Diamond Therapeutics' higher probable upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to BDTX or CGEN? In the previous week, Compugen had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 3 mentions for Compugen and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.92 beat Compugen's score of 0.21 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Compugen 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor BDTX or CGEN? Compugen received 257 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 64.30% of users gave Compugen an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% CompugenOutperform Votes30864.30% Underperform Votes17135.70% Is BDTX or CGEN more profitable? Compugen has a net margin of 2.67% compared to Black Diamond Therapeutics' net margin of 0.00%. Compugen's return on equity of 2.62% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% Compugen 2.67%2.62%1.36% Which has more risk and volatility, BDTX or CGEN? Black Diamond Therapeutics has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500. Which has better valuation & earnings, BDTX or CGEN? Compugen has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.83Compugen$33.46M3.81-$18.75M$0.0271.50 Do institutionals and insiders hold more shares of BDTX or CGEN? 95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryCompugen beats Black Diamond Therapeutics on 11 of the 16 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$137.49M$2.95B$5.06B$8.89BDividend YieldN/A1.90%4.97%4.06%P/E Ratio-1.8317.8689.0213.30Price / SalesN/A222.321,207.2881.01Price / CashN/A160.0839.1736.03Price / Book1.084.906.085.74Net Income-$82.44M-$41.63M$119.07M$225.93M7 Day Performance-14.74%-4.73%-1.84%-1.32%1 Month Performance-24.30%-6.53%-3.65%0.60%1 Year Performance8.97%25.63%31.62%26.23% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.43-4.7%$15.50+537.9%+8.0%$144.29MN/A-1.8390Positive NewsCGENCompugen2.7226 of 5 stars$1.43-0.7%$4.00+179.7%+121.5%$128.50M$33.46M71.5068INBXInhibrx1.2884 of 5 stars$14.04-1.7%N/A-36.9%$206.86M$1.63M0.00166SPPISpectrum PharmaceuticalsN/A$1.03flatN/AN/A$211.41M$10.11M-2.8686ITOSiTeos Therapeutics3.4955 of 5 stars$7.85-0.6%$31.50+301.3%-23.0%$288.62M$12.60M0.0090CCCCC4 Therapeutics2.652 of 5 stars$4.05-2.4%$10.00+146.9%+139.6%$292.94M$20.76M0.00150Analyst ForecastCDXCChromaDex3.9237 of 5 stars$7.50-0.3%$8.00+6.7%+417.2%$574.40M$83.57M750.75106Analyst DowngradeIGMSIGM Biosciences4.7018 of 5 stars$9.77+2.4%$16.13+65.1%+63.3%$567.29M$2.13M0.00190ABVXABIVAX Société Anonyme3.0118 of 5 stars$8.86-0.6%$39.80+349.2%-19.6%$563.96MN/A0.0061HUMAHumacyte2.8803 of 5 stars$4.41-0.2%$11.00+149.4%+71.6%$556.30M$1.57M0.00150Insider TradeATXSAstria Therapeutics1.7093 of 5 stars$9.58-1.7%$25.60+167.2%+110.5%$550.23MN/A0.0030Analyst Revision Related Companies and Tools Related Companies CGEN Competitors INBX Competitors SPPI Competitors ITOS Competitors CCCC Competitors CDXC Competitors IGMS Competitors ABVX Competitors HUMA Competitors ATXS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
